191 related articles for article (PubMed ID: 14699176)
21. How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?
Wang G; Lau EW; Shakher R; Rischin D; Ware RE; Hong E; Binns DS; Hogg A; Drummond E; Hicks RJ
Cancer; 2007 Jan; 109(1):117-24. PubMed ID: 17133406
[TBL] [Abstract][Full Text] [Related]
22. Incidental colonic focal lesions detected by FDG PET/CT.
Gutman F; Alberini JL; Wartski M; Vilain D; Le Stanc E; Sarandi F; Corone C; Tainturier C; Pecking AP
AJR Am J Roentgenol; 2005 Aug; 185(2):495-500. PubMed ID: 16037527
[TBL] [Abstract][Full Text] [Related]
23. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
[TBL] [Abstract][Full Text] [Related]
24. Early experience with PET scanning in thoracic tumours.
Kutlu CA; Pastorino U; Maisey M; Goldstraw P
J Cardiovasc Surg (Torino); 2001 Jun; 42(3):403-7. PubMed ID: 11398041
[TBL] [Abstract][Full Text] [Related]
25. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
26. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
Graeber GM; Gupta NC; Murray GF
J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
[TBL] [Abstract][Full Text] [Related]
27. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
28. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
29. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
Lardinois D; Weder W; Roudas M; von Schulthess GK; Tutic M; Moch H; Stahel RA; Steinert HC
J Clin Oncol; 2005 Oct; 23(28):6846-53. PubMed ID: 16192576
[TBL] [Abstract][Full Text] [Related]
30. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
31. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.
Schöder H; Yeung HW; Gonen M; Kraus D; Larson SM
Radiology; 2004 Apr; 231(1):65-72. PubMed ID: 14990824
[TBL] [Abstract][Full Text] [Related]
32. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM
Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451
[TBL] [Abstract][Full Text] [Related]
33. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
[TBL] [Abstract][Full Text] [Related]
34. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT.
Even-Sapir E; Lerman H; Gutman M; Lievshitz G; Zuriel L; Polliack A; Inbar M; Metser U
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):541-52. PubMed ID: 16491423
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
36. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous and subcutaneous imaging on FDG-PET: benign and malignant findings.
Blumer SL; Scalcione LR; Ring BN; Johnson R; Motroni B; Katz DS; Yung EY
Clin Nucl Med; 2009 Oct; 34(10):675-83. PubMed ID: 19893399
[TBL] [Abstract][Full Text] [Related]
38. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
39. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management.
Basu S; Houseni M; Alavi A
Nucl Med Commun; 2008 Apr; 29(4):367-73. PubMed ID: 18317302
[TBL] [Abstract][Full Text] [Related]
40. The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT.
Lee JC; Hartnett GF; Hughes BG; Ravi Kumar AS
Nucl Med Commun; 2009 May; 30(5):333-7. PubMed ID: 19262416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
